Cadila Healthcare Gains Over 2% After Unit Buys Drug For Menkes Disease Cadila Healthcare said that its US subsidiary has acquired an experimental drug from Cyprium for treating Menkes disease, which is a rare recessive pediatric disease
Updated: February 25, 2021 11:33 am IST
At 11:20 am, the shares of Cadila Healthcare were trading higher by 1.9 per cent on BSE
Cadila Healthcare shares rose more than 2 per cent in mid-morning trading after the pharma company said its US subsidiary has acquired an experimental drug from Cyprium for treating Menkes disease. At 11:20 am, the shares of Cadila Healthcare were trading at Rs 442.50, higher by 1.9 per cent, on the BSE. The shares have touched an intra-day high of Rs 444.70 and a low of Rs 436.35 thus far.